nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.10.2010 | Guidelines

Procedure guidelines for PET/CT tumour imaging with ⁶⁸Ga-DOTA-conjugated peptides: ⁶⁸Ga-DOTA-TOC, ⁶⁸Ga-DOTA-NOC, ⁶⁸Ga-DOTA-TATE

verfasst von: Irene Virgolini, Valentina Ambrosini, Jamshed B. Bomanji, Richard P. Baum, Stefano Fanti, Michael Gabriel, Nikolaos D. Papathanasiou, Giovanna Pepe, Wim Oyen, Clemens De Cristoforo, Arturo Chiti

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

The aim of these guidelines is to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin (SST) receptor PET/CT imaging using ⁶⁸Ga-DOTA-conjugated peptides, analogues of octreotide, that bind to SST receptors. This imaging modality should not be regarded as the only approach to visualizing tumours expressing SST receptors or as excluding other imaging modalities useful for obtaining comparable results. The corresponding guidelines of ¹¹¹In-pentetreotide scintigraphy imaging have been considered and partially integrated with this text. The same has been done with the relevant and recent literature in this field and the final result has been discussed by distinguished experts.

Balon HR, Goldsmith SJ, Siegel BA, Silberstein EB, Krenning EP, Lang O, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med 2001;42(7):1134–8.PubMed

Bombardieri E, Ambrosini V, Aktolun C, Baum RP, Bishof-Delaloye A, Del Vecchio S, et al. (111)In-Pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37(7):1441–8.CrossRefPubMed

Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology. 2009;90(2):184–9.CrossRefPubMed

Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging 2007;34(7):982–93.CrossRefPubMed

Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24(4):389–427.CrossRefPubMed

Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30(5):781–93.CrossRefPubMed

Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol. 2001;12 Suppl 2:S51–61.CrossRefPubMed

Olsen JO, Pozderac RV, Hinkle G, Hill T, O'Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med 1995;25(3):251–61.CrossRefPubMed

Briganti V, Sestini R, Orlando C, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors. Clin Cancer Res 1997;3:2385–91.PubMed

10.

Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med 2000;44(1):42–9.PubMed

11.

Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med 1998;25(10):1396–403.CrossRefPubMed

12.

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716–31.CrossRefPubMed

13.

Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 1998;25:639–58.CrossRefPubMed

14.

Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111 pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med 1995;36:542–49.PubMed

15.

Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38(6):853–8.PubMed

16.

Kowalski J, Henze M, Schuhmacher J, Maecke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 2003;5:42–8.CrossRefPubMed

17.

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34(10):1617–26.CrossRefPubMed

18.

Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28(12):1751–7.CrossRefPubMed

19.

Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging 2003;30(10):1338–47.CrossRefPubMed

20.

Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51(5):669–73.CrossRefPubMed

21.

Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51(3):353–9.CrossRefPubMed

22.

Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48(4):508–18.CrossRefPubMed

23.

Ambrosini V, Marzola MC, Rubello D, Fanti S. (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37(1):46–8.CrossRefPubMed

24.

Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, et al. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 2010;37(1):49–57.CrossRefPubMed

25.

Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer 2008;112(11):2447–55.CrossRefPubMed

26.

Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35(8):1431–8.CrossRefPubMed

27.

Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother 2008;62(10):667–71.CrossRefPubMed

28.

Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009;50(12):1927–32.CrossRefPubMed

29.

Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009;30(4):281–6.CrossRefPubMed

30.

Klutmann S, Bohuslavizki KH, Brenner W, Behnke A, Tietje N, Kröger S, et al. Somatostatin receptor scintigraphy in postsurgical follow-up examinations of meningioma. J Nucl Med 1998;39(11):1913–7.PubMed

31.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med 2005;46(5):763–9.PubMed

32.

Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging 2010;37(1):67–77.CrossRefPubMed

33.

Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50(8):1214–21.CrossRefPubMed

34.

Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2010;37(4):722–7.CrossRefPubMed

35.

Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, et al. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 2002;29:147–57.CrossRefPubMed

36.

Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50:1427–34.CrossRefPubMed

37.

EANM Radiopharmacy Committee. Guidelines on current good radiopharmacy practice (cGRPP) in the preparation of radiopharmaceuticals. European Association of Nuclear Medicine; 2007. http://www.eanm.org/scientific_info/guidelines/gl_radioph_cgrpp.pdf. Accessed 24 June 2010.

38.

Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre-Chauvet A, et al; Radiopharmacy Committee of the EANM. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging 2010;37:1049–62.CrossRefPubMed

39.

Velikyan I, Beyer GJ, Långström B. Microwave-supported preparation of 68Ga bioconjugates with high specific radioactivity. Bioconjug Chem 2004;15:554–60.CrossRefPubMed

40.

Meyer GJ, Maecke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging 2004;31:1097–104.CrossRefPubMed

41.

Zhernosekov KP, Filosofov DV, Baum RP, Aschoff P, Bihl H, Razbash AA, et al. Processing of generator-produced 68Ga for medical application. J Nucl Med 2007;48:1741–8.CrossRefPubMed

42.

Di Pierro D, Rizzello A, Cicoria G, Lodi F, Marengo M, Pancaldi D, et al. Radiolabelling, quality control and radiochemical purity assessment of the octreotide analogue 68Ga DOTA NOC. Appl Radiat Isot 2008;66:1091–6.CrossRefPubMed

43.

Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478–85.CrossRefPubMed

44.

Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, et al. A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 2007;28:870–5.CrossRefPubMed

45.

Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2008;35:72–9.CrossRefPubMed

Titel: Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE
verfasst von: Irene Virgolini
Valentina Ambrosini
Jamshed B. Bomanji
Richard P. Baum
Stefano Fanti
Michael Gabriel
Nikolaos D. Papathanasiou
Giovanna Pepe
Wim Oyen
Clemens De Cristoforo
Arturo Chiti
Publikationsdatum: 01.10.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1512-3

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2010

Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy

A fast cardiac gamma camera with dynamic SPECT capabilities: design, system validation and future potential

Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein

Before and after treatment 18F-FDG PET/CT images in a patient with cutaneous T-cell lymphoma

Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters

PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG